MGAT2 and obesity due to melanocortin 4 receptor deficiency: Taken together, newly identified insights into the pharmacological effects of the MGAT2 inhibitor in this study further support the concept that pharmacological MGAT2 inhibition could be used as a treatment for obesity and its related metabolic diseases.